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Abstract
Background: Indonesia ranking third in the world, regarding leprosy burden. Chemoprophylaxis is effective in
reducing risk of developing leprosy among contacts. ‘Blanket approach’ is an operational strategy for leprosy post-
exposure prophylaxis in which all members of an isolated community, high endemic for leprosy are screened and
given a single dose of rifampicin (SDR) in the absence of signs and symptoms of leprosy. The objective is to assess
the operational feasibility of a population-wide ‘blanket’ administration of SDR for leprosy prevention in isolated
communities in a remote island.
Methods: A prospective follow-up study was conducted in the year 2014, 2015 and 2016 in Lingat village of Selaru
Island, Indonesia. During the first two visits, screening and SDR were provided, whereas only screening was
conducted during the third visit. The demographic and clinical data were used for a descriptive analysis of the
project coverage and leprosy epidemiology.
Results: During the first two visits, 1671 persons (88%) were screened, 1499 (79%) received SDR, and 213 (11%) were
excluded based on the exclusion criteria. During the first two visits, 43 (2.6%) cases were diagnosed with leprosy with
a rate of 2263 per 100,000 population. The prevalence was highest in the age groups 15–24 and 25–49 years. Total,
14 (33%) cases had MB and 29 (67%) PB leprosy. Two cases (5%) had grade 2 disability. During the third visit, 10 new
leprosy cases, with no grade 2 disability, were detected out of 1481 screened persons at the rate of 484 cases per
100,000 population (n = 2065 population in 2016). Among those screened during the third visit, there was a 50%
reduction of leprosy among those who had previously received SDR compared to those who had not.
Conclusion: With adequate planning and some additional investment, it is feasible to implement a blanket approach
of chemoprophylaxis in a remote island of Indonesia, although effort needs to be made to cover as many people as
possible in the first visit. Contingency plans need to be made to actively follow this village closely in the coming years
and continue leprosy elimination efforts until no new cases are found any more.
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Background
Leprosy is an infectious disease caused by Mycobacter-
ium leprae [1]. The disease burden has reduced in the
last two decades, for which multidrug therapy (MDT) is
largely credited [2, 3]. Unfortunately, this has not led to
the incidence based global elimination of leprosy [4].
Currently, 136 countries report leprosy (210,758 new
cases in 2015), indicating that transmission of M. leprae
has not yet been interrupted [5]. Leprosy causes serious
and irreversible nerve damage, which is a leading cause
of disability among communicable diseases in developing
countries [6]. Globally, 14,059 cases (0.25/100,000 popu-
lation) were detected with grade 2 disability in 2015 [5].
Indonesia is an archipelagic island country with a
population of 237.6 million [7]. Half of its population
lives in rural areas (census 2010) and there are over 300
ethnic groups in the country [8]. The geographical and
demographical diversity challenges health service delivery,
especially in remote areas [9]. Indonesia contributes 8%
(17,202 new cases in 2015) to the global leprosy burden,
and ranks third after India and Brazil [5]. The majority
(84%) of new cases have the multibacillary (MB) form of
the disease, which is considered largely responsible for the
transmission due to high bacterial load. Following intensi-
fied efforts by the National Leprosy Control Programme
(NLCP) of the Indonesian government, the new case
detection rate declined between 2005 and 2014 by 13.5%
[10]. However, a recent modelling study predicted that the
2020 London Declaration target of leprosy elimination in
terms of interruption of transmission will be difficult to
achieve for Indonesia [11–13]. Stigmatization of leprosy is
a severe problem in Indonesia and this also hampers
efforts to find and treat leprosy patients [14–16].
Initially, leprosy control and later elimination efforts fo-
cused heavily on finding and treating patients [17], but atten-
tion is now shifting more towards prevention of the disease.
The latest WHO Global Leprosy Strategy 2016–2020 has
early case finding (through contact tracing and screening)
high on the agenda [18]. Preventive interventions that are
currently being considered are chemoprophylaxis and immu-
noprophylaxis [19]. Chemoprophylaxis or post-exposure
prophylaxis (PEP) is often combined with other approaches
such as contact tracing or ‘blanket’ approaches [20, 21].
‘Blanket’ approach is a strategy in which all members in a
given community are screened by trained health workers for
leprosy and given post-exposure prophylaxis (PEP). This
approach is potentially suitable for secluded high-endemic
areas, such as small islands communities. The leprosy con-
trol programme of Indonesia is introducing new prevention
methods. It is the first country in Southeast Asia to pilot PEP
with a single dose of rifampicin (SDR) within the leprosy
control programme for selective highly endemic districts.
Indonesia gained valuable experience with contact tracing
followed by SDR in Sampang district (East Java), Bima
district (West Nusa Tenggara), and the blanket approach in
Mumugu village, Papua. These experiences however, have
not yet been documented scientifically and disseminated for
wider learning. A single but important study from Indonesia
concluded that the blanket approach with rifampicin is
effective in reducing the incidence of leprosy [22]. It is very
important to explore the feasibility and effectiveness of the
blanket approach in detail, because the national programme
plans to expand SDR to other highly endemic areas, many of
them being remote islands.
The blanket approach in Lingat Village was imple-
mented under the Leprosy Post Exposure Prophylaxis
(LPEP) programme. The objective of this paper is to
assess the operational feasibility of the population-wide
‘blanket’ administration of SDR for leprosy prevention in
isolated communities, by documenting the implementa-
tion process and initial results of a pilot project in a
remote island of Indonesia.
Methods
Intervention site
The blanket approach was conducted in Lingat village
(population around 1900 in year 2014) in three visits in
November 2014, November 2015 and November 2016.
The village is situated on Selaru Island (Southeast Maluku
West), which is a part of Tanimbar Islands in Maluku
(Fig. 1).
The village can only be reached by boat and every year,
due to poor weather conditions, the village is extremely
hard to reach for several months. The NLCP received
verbal information from the health workers of Tanimbar
Islands that around 30 people were suspected of having
leprosy. Photographs of the persons with patches were
inspected by a leprosy expert. After initial confirmation,
the government and non-governmental partners discussed
the feasibility and agreed to organize a PEP blanket
campaign. The selection criteria for the blanket approach
are listed in Table 1.
Study design
This is a three year prospective follow-up study, where
implementation of the SDR intervention was completed
during the first two visits with a year interval. During
the third visit, the complete population of the island was
screened again to establish the number of new cases
arising since the implementation of the intervention
during the first two visits. The campaign team first listed
households, screened all available individuals and
detected new leprosy cases, which were subsequently
put on MDT. The remaining eligible population was
offered SDR, after checking for the exclusion criteria, i.e.
absence from the house, refusing consent, pregnant, sus-
pect of having leprosy or diagnosed with leprosy, history
of receiving rifampicin (for leprosy or any other disease)
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in the past two years, under the age of 2 years, and
suspect of having tuberculosis. The aim was to reach at
least 80% of the population, because a high coverage is
desired to break the transmission chain by sufficiently
reducing the bacterial load of M. leprae in the popula-
tion. The target was not achieved during the first visit
because many people were away from their houses to
earn livelihood. Therefore, the first (baseline) visit was
extended with a second visit in November 2015 to cover
the absentees of the first year visit. Individuals who had
received SDR during the first visit were not re-examined
for leprosy during the second visit. During the study
period, SDR was given only once to an individual.
Study infrastructure
During the first visit, two teams were formed, each led
by a medical doctor and supported by 2–3 leprosy health
workers. The mode of transportation was speed motor
boats, leaving from Saumlaki (the capital of the district)
and sailing for 3 h to reach Lingat village. Each visit
lasted 5–6 days. However, the number of teams was
increased to five and six for the second and third visits.
The details of the implementation process for all three
visits are presented in Table 2.
A standard set of data were collected on paper forms,
and later entered electronically. An additional file shows
this in more detail (see Additional file 1). The demo-
graphical and clinical data were used for the descriptive
analysis and assessment of the project coverage and epi-
demiological situation.
Statistical analysis
Data were subsequently entered into an excel-based
electronic database during the visits. A unique identifica-
tion number was generated for all personal records and
matched to identify any previous contacts receiving
SDR, but who later proved to be a leprosy case. Further-
more, contacts of the first and second visits were
matched to check for overlap, because the second visit
aimed to cover only those who missed the screening and
SDR during the first visit. Data cleaning included assess-
ment of missing values and logic checks for the related
variables, e.g., age and dosage of rifampicin. Frequency
distributions and subgroup analyses were performed for
descriptive analysis. Groups were formed based on sex,
age, type of leprosy and disability grade.
Results
The officially registered population of the island in
November 2014 was 1900, which increased to 2065 by
November 2016. During the first two visits, 1743 (92%)
of this estimated population were listed, 1671 (88%)
screened, and 1499 (79%) received SDR. The screening
covered 1241 people during the first visit, the remaining
Fig. 1 Location of Selaru Island in Indonesia (Source: Wikimedia Commons)
Table 1 Feasibility criteria for a blanket approach campaign
Criteria Desired Eligibility
Geographical location Remote Island
The degree of isolation More than 80% of the community members
can be considered as contacts
Leprosy endemicity CDRa > 100/100,000
Sociocultural conditions Openness for outsiders
Logistics and information Mode of transportation, best time to visit
as per weather conditions
Sustainability The availability and training of health worker(s)
to continue providing leprosy services
aCDR Case Detection Rate
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430 people during the second visit, and 1481 people dur-
ing the third visit (Table 3).
In the first two visits, the male-female ratio of those
screened and receiving SDR was nearly 1:1. In total, 43
(2.6%) persons were diagnosed with leprosy with the rate
of 2263 per 100,000 population (n = 1900), of whom 16
(37%) were female. During the third visit, 10 persons
were diagnosed with leprosy at the rate of 484 per
100,000 population (n = 2065), with equal distribution of
cases by gender.
Table 4 shows the number of people screened and
detected with leprosy by age group. In all the visits, children
in the age 2–14 years formed the largest group, followed by
adults aged 25–49 years, and adults above 50 years. In total
43 new leprosy cases (2.57%; 95% CI: 1.84–3.36%) were
detected during the first two visits. Prevalence of leprosy
was highest in those aged 15–24 years and 25–49 years (4.7
and 4.6%, respectively). During the third visit, 10 new
leprosy cases (0.68%; 95% CI: 0.35–1.29%) were detected
and treated. The incidence was again high in the age group
of 25–49 years (70% cases).
In the first two visits, 14 of the cases had MB leprosy
(33%; 95% CI: 19–47%), and 29 PB leprosy (67%; 95%
CI: 53–82%). Two people (5%; 95% CI: -2.18-6.18%) had
grade 2 disability. In the third visit, 6 cases had MB
leprosy (60%; 95% CI: 27–86%) out of 10 new cases, with
no grade 2 disability (Table 5).
During the first two visits, SDR was administered to
1499 persons. Out of the total number screened who had
no signs or symptoms of leprosy, 213 were excluded on
the basis of the exclusion criteria (Table 6). Being absent
and under 2 years of age were the most common reasons
for exclusion. During the third visit, 1481 people were
screened, of whom 1071 had received SDR during the
earlier visits and 410 had not because of exclusion criteria
or absence. The number of new cases among the 1071
who had received SDR was 6 and the number of cases
among the 410 who had not received SDR was 4 (Table 7).
The odds ratio is 0.57 (95% CI: 0.16–2.03), indicating that
the odds of having leprosy are lower in the exposed (SDR)
than in the non-exposed (no SDR) group.
Discussion
The blanket approach in Lingat Village was implemented
under the Leprosy Post Exposure Prophylaxis (LPEP)
programme. The aim of LPEP is to assess impact and
Table 2 Standard steps followed while implementing the
blanket approach
Steps Details
1. Communication Officially inform the local stakeholders about the
blanket approach and schedule
2. Planning and
logistics
- Training of the team
- - Arrangements for transportation, medicines,
supplies and stationary
3. Travel A courtesy call to the village head
4. IEC Community information on health, leprosy and
purpose of visit
5. Screening Door to door:
- Line listing
- Informed consent
- Physical examination to diagnose leprosy
- - Checking eligibility criteria
6. Medication/
Referral
- MDT to the newly identified cases
- SDR to the eligible individuals
(only in the first two visits)
- - Biological sample collection for difficult
to diagnose cases
7. Data collection Simultaneously with step 5 and 6
8. Training of local
health worker
- MDT treatment
- Management of leprosy complications
- - Follow-up of those who are absent or excluded
to receive SDR
Table 3 The number of individuals listed (males and females), screened, found with leprosy, and given SDR
Visit Sex Listed Screened Leprosy Prevalence (% screened) SDR
Survey 1 (2014) Male 621 589 17 2.9% 520
Female 668 652 12 1.8% 584
Sub total 1289 1241 29 2.3% 1104
Survey 2 (2015) Male 232 214 10 4.7% 194
Female 222 216 4 1.9% 201
Sub total 454 430 14 3.3% 395
Total (population 1900 in 2014) 1743 (92%) 1671 (88%) 43 2.6% 1499 (79%)
Incidence
Survey 3 (2016) Male 954 717 5 0.7% NA
Female 1000 764 5 0.7%
Total (population 2065 in 2016) 1954 (95%) 1481 (72%) 10 0.7%
The population was increased by the 3rd survey, which also included new individuals
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feasibility of contact tracing and administration of single
dose of rifampicin (SDR) to asymptomatic contacts of
leprosy cases in the six countries (India, Nepal, Myanmar,
Sri Lanka, Tanzania, Indonesia) [23]. Indonesia however, is
the only country where the blanket approach is applied. In
the other countries SDR is provided to close contacts of
leprosy patients only.
The objective of the blanket approach campaign was
to survey the complete target population and provide all
eligible individuals with SDR in one visit in a high en-
demic, isolated population. Because the desired coverage
of more than 80% was not reached, it was decided to
conduct a second visit in the next year to include those
who were missed during the first visit. The inadequate
coverage in the first visit was mainly due to lack of
awareness in the population regarding leprosy and its
consequences, although the officials and inhabitants
were well informed prior to the visit (Table 2). The
absentees were out to earn livelihood, because there
were wage losses when staying at home in receiving the
intervention. The skin examination can only be done in
daylight, therefore late evening or early morning timings
were not suitable, although this could increase the
coverage. Certainly, the first visit increase awareness,
and the second visit emphasized seriousness of the inter-
vention, which helped to increase the coverage in the
following visits. By the end of second visit, 92% were
listed and 88% were screened. A third (follow-up) visit
after a year was conducted to monitor the number of
new cases arising in the population after the intervention
during the two baseline visits. Among the people
screened during the third visit, there was an apparent
reduction of leprosy of around 50% among those who
had previously received SDR compared to those who
had not. However, a high rate of transmission is evident
as 3 child cases (2–14 age group) were detected in the
third visit, and 2 of them had SDR in the previous visits.
Studies on effectiveness have been done before, but not
always with clear conclusions, due to methodological
shortcomings. In 1988, a non-controlled trial with SDR
25 mg/kg dose was implemented in the Southern
Marquesas Islands [24–26]. The intervention achieved
98.7% coverage (2715 received SDR out of 2786 inhabi-
tants), and additionally covered 3144 South Marquesans
living elsewhere in French Polynesia. As a result, new 5
cases were detected in the next 10 years among treated
population, which was significantly less than the 17
expected cases in a hypothetical situation of unchanged
transmission rate. In comparison to the Polynesian
population that did not receive the intervention, chemo-
prophylaxis was found to have an additional protective
effect of 35–40%. In 1990, Pacific islands implemented
chemoprophylaxis in the Federated States of Micronesia,
Kiribati and the Republic of the Marshall Islands [27].
The screening covered 70% of the population for two
consecutive years, including chemoprophylaxis (both
years) of rifampicin-ofloxacin-minocycline (ROM) to
adults and rifampicin only to children under 15 years of
age [28]. By 1999 a substantial reduction in case detec-
tion was observed, but it could not be established that
this was due to intervention [27].
In the year 2000, five high endemic islands in Indonesia
piloted chemoprophylaxis with a defined control group
[22] with 600 mg rifampicin for adults and 300 mg for
Table 4 Number of cases screened and detected with leprosy in different age groups
Survey 1 (2014) Survey 2 (2015) Survey 3 (2016)
Age group in years Screened Leprosy Prevalence % Screened Leprosy Prevalence % Screened Leprosy Incidence %
Under 2 66 0 0 5 0 0 48 0 0.0
02–14 514 8 1.6 164 1 0.6 469 3 0.6
15–24 100 3 3 49 4 8.2 142 0 0.0
25–49 297 12 4 119 7 5.9 449 7 1.6
≥ 50 264 6 2.3 93 2 2.2 373 0 0.0
Total 1241 29 2.3 430 14 3.3 1481 10 0.7
Table 5 PB-MB and G2D distribution according to sex in
leprosy cases identified during three visits
Visit Sex Leprosy MB % PB % G2D %
Cases (2014) Male 17 8 47 9 53 2 12
Female 12 4 33 8 66 0 0
Sub total 29 12 41 17 59 2 12
Cases (2015) Male 10 0 0 10 100 0 0
Female 4 2 50 2 50 0 0
Sub total 14 2 14 12 86 0 0
Total 43 14 33 29 67 2 5
Cases (2016) Male 5 3 60 2 40 0 0
Female 5 3 60 2 40 0 0
Sub total 10 6 60 4 40 0 0
Grand Total 53 20 38 33 62 2 4
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children (6–14 years old) with approximately 3.5 months
between doses. Two types of chemoprophylactic interven-
tion strategies (blanket approach and contact tracing
SDR) were compared with a control group (no chemo-
prophylaxis). In contact tracing SDR, prophylaxis was
given to eligible contacts of all known and newly found
leprosy patients only, unlike the blanket approach. The
population cohort of 3965 persons was actively screened
before the intervention and subsequently once a year for
three years. The yearly incidence rate in the control group
was 39/10,000; the cumulative incidence after three years
was significantly lower in the blanket group. No difference
was found between the contact tracing SDR and the con-
trol groups. This study showed that population-based
prophylaxis was associated with a reduced leprosy
incidence in the first three years after implementation.
Subsequently the COLEP trial in Bangladesh, in which
SDR was given to contacts of leprosy patients, showed an
overall reduction in the incidence of leprosy in the first
two years of 57% [22]. The initial protective effect was
maintained, but no difference in incidence was seen
between the placebo and rifampicin groups beyond two
years [22, 29, 30].
Based on the preceding studies, it can be expected that
the provision of chemoprophylaxis in a blanket approach
to a well-defined highly endemic population will help re-
duce the transmission of M. leprae in that population.
Apart from overall reduction of leprosy cases in the
coming years, we do expect a possible relative increase
in MB cases because SDR is more effective in reducing
the PB cases due to lower bacterial load than MB. The
increase in MB cases can also be due to previously
missed early MB cases as it is often difficult to diagnose
such cases through screening. One can expect that po-
tential MB and PB cases that are early in the incubation
period may respond well to SDR, but not those MB
cases which are already advanced in their clinical stage.
There are however, several important remaining questions
regarding implementation aspects of such approach, and
on the intensity and duration of active follow-up. It cannot
be expected that leprosy will disappear by itself after a
one-off intervention, as the experience of the Federated
States of Micronesia and the Marshall Islands sadly
demonstrated. The current study in Lingat village showed
that the campaign could not be completed in just one
visit. In order to optimize the effect of such campaign, an
effort should be made to reach as much people in a single
first round or to leave limited time between the first and
second round, to avoid unidentified leprosy patients
continuing to spread M. leprae in their surroundings. A
one-year intercept is already quite long, and it would be
preferable to conduct the second round within 6 months.
Conclusion
The study in Lingat village shows that the blanket
approach is in principal operationally feasible in terms of
staff and time investment. It could likely be implemented
in similar locations and sociocultural settings. The popula-
tion preparation (prior information on timelines, methods
and objectives of survey) is crucial in attaining the desired
coverage. The people generally showed no resistance to
the intervention and mostly accepted the SDR without
refusal of consent. Most individuals excluded from SDR
had genuine contraindications for receiving SDR. The
intervention achieved a good balance in reaching males
and females. The number of child cases was high (21%),
indicating active transmission of M. leprae in the commu-
nity. We recommend a close monitoring of children in the
future, especially the under 2 years group, which was ex-
cluded from receiving SDR in the campaign. Furthermore,
the intervention covered a relatively large group of chil-
dren, probably because this group stays at home during
the day, compared to other household members who are
often out working.
Table 6 Number and Reasons for Exclusion from SDR in the first two visits
Visit Absent Refused Consent Pregnant Suspect Leprosy Rifampicin History Under age 2 Suspect TB Total
Contact (2014) 48 0 13 11 7 66 12 157
Contact (2015) 24 0 5 11 4 5 7 56
Total 72 0 18 22 11 71 19 213
Table 7 The details of new cases detected in the third visit
SDR history SDR in visit Age Gender Type
Received 1st 3 M PB
Received 2nd 5 M PB
Received 1st 25 M MB
Received 1st 27 F MB
Received 1st 44 M PB
Received 1st 49 F MB
Not received NA 4 M MB
Not received NA 32 F PB
Not received NA 33 F PB
Not received NA 49 F MB
NA Not applicable
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So far, SDR appeared to show protective effect against
leprosy during the third visit. We recommend to
conduct a fourth visit in Lingat village after one year to
re-screen the full population, so that the effectiveness of
the SDR can be further established. There is no evidence
yet regarding the number of rounds required to control
or eliminate leprosy is such setting, and the desired time
interval between rounds. Because we expect to find
more leprosy cases in future, contingency plans need to
be made to actively follow this village closely in the
coming years and continue leprosy elimination efforts
until no new cases are found any more.
Additional file
Additional file 1: Type of data collected during the visits of blanket
campaign. Type of data collected during the visits of blanket campaign.
(DOCX 13 kb)
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